Alto Neuroscience, Inc.

Alto is a clinical-stage biopharmaceutical company that develops targeted therapies for neuropsychiatric conditions. The company utilizes a proprietary precision psychiatry platform that evaluates brain-based biomarkers through electroencephalography, neurocognitive assessments, wearable technology, and genomic data to identify patients likely to benefit from specific interventions. Its clinical development pipeline comprises seven assets, including ALTO-207, ALTO-300, ALTO-100, ALTO-101, and ALTO-203, targeting disorders such as major depressive disorder, bipolar depression, treatment-resistant depression, cognitive impairment associated with schizophrenia, and Parkinson’s disease. Its products are developed for individuals diagnosed with psychiatric and neurological disorders.

The company conducts clinical trials across the United States, having gathered biomarker data from over 2,000 participants across more than 70 clinical sites. Its clinical operations also examine compounds previously evaluated or approved in international regions including Europe and Australia. The provided text does not disclose the location of its corporate headquarters.

Summary of the business section of Alto Neuroscience's latest annual report, written by StockData.

“As of December 31, 2025, we had 68 total employees, including 66 in the United States and two in Australia.”